VALIANTLAB Latest Share Price (VALIANTLAB)
TODAY IN ONE LINE
With a market cap of ₹635.73 Cr., it trades at a P/E of 39.68. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
VALIANTLAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 74.9% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 36.3% YoY
- ●Poor Capital ReturnsLow ROE of 1.7%
- ●Rising Receivables vs SalesReceivables grew 49.2% outpacing sales growth of -26.7%
Latest VALIANTLAB News
What changed recently?
Recent events, corporate actions, and announcements.
VALIANTLAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VALIANTLAB, framed against the sector median so the premium or discount is obvious at a glance.
VALIANTLAB trades at a P/E of 39.68× and P/B of 2.04×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
VALIANTLAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for VALIANTLAB — derived from the latest tape, not yesterday's close.
VALIANTLAB last traded at ₹104.89 with an intraday range of ₹103–₹109.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹104.89| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 120.79 | +15.90 | +15.16% |
| R3 | 114.59 | +9.70 | +9.25% |
| R2 | 111.90 | +7.01 | +6.68% |
| R1 | 108.39 | +3.50 | +3.34% |
| PIVOT | 105.70 | 0.81 | 0.77% |
| CURRENT | 104.89 | — | — |
| S1 | 102.19 | -2.70 | -2.57% |
| S2 | 99.50 | -5.39 | -5.14% |
| S3 | 95.99 | -8.90 | -8.48% |
| S4 | 89.79 | -15.10 | -14.39% |
VALIANTLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Inside opening range
VALIANTLAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for VALIANTLAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
VALIANTLAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹635.73 Cr. and reported EPS of ₹1.75.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 133 | 237 ▲ 78.0% |
| Sales Growth YoY %Derived | -26.74% | 78.04% |
| Other Income | 5 | 2 ▼ 57.3% |
| Total Income | 139 | 240 ▲ 72.7% |
| 117 | 197 ▲ 69.1% | |
| Gross ProfitDerived | 17 | 40 ▲ 140.2% |
| Gross Margin %Derived | 12.58% | 16.97% |
| 21 | 34 ▲ 58.0% | |
| EBITDA (Operating Profit)Derived | -5 | 6 ▲ 236.6% |
| OPM %Derived | -3.51% | 2.69% |
| 2 | 8 ▲ 250.2% | |
| Profit Before Tax (PBT) | -2 | 1 ▲ 150.8% |
| 1 | 4 ▲ 486.1% | |
| Effective Tax %Derived | -45.52% | 525.40% |
| Total Profit for Period | -2 | -3 ▼ 48.5% |
| Net Profit (Owner's PAT)Derived | -2 | -3 ▼ 48.5% |
| Net Profit Margin %Derived | -1.65% | -1.38% |
| PAT Growth YoY %Derived | -788.67% | -48.46% |
| Earnings Per Share (EPS ₹) | -0.41 | -0.60 ▼ 46.3% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 117.5% |
| Total Expenses (incl. D&A & Interest) | 140 | 239 ▲ 70.3% |
| Material Cost % of RevenueDerived | 84.10% | 80.35% |
| Employee Cost % of RevenueDerived | 3.29% | 2.95% |
| Other Cost % of RevenueDerived | 12.80% | 11.33% |
| Interest Coverage (x)Derived | -38.63x | 0.18x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 182 | 133 ▼ 26.7% | 237 ▲ 78.0% | |
| Sales Growth YoY %Derived | — | -26.74% | 78.04% | |
| Other Income | 10 | 5 ▼ 43.9% | 2 ▼ 57.3% | |
| Total Income | 192 | 139 ▼ 27.6% | 240 ▲ 72.7% | |
168 | 117 ▼ 30.7% | 197 ▲ 69.1% | ||
| Gross ProfitDerived | 14 | 17 ▲ 21.6% | 40 ▲ 140.2% | |
| Gross Margin %Derived | 7.58% | 12.58% | 16.97% | |
22 | 21 ▼ 3.4% | 34 ▲ 58.0% | ||
| EBITDA (Operating Profit)Derived | -8 | -5 ▲ 44.3% | 6 ▲ 236.6% | |
| OPM %Derived | -4.62% | -3.51% | 2.69% | |
2 | 2 ▲ 11.0% | 8 ▲ 250.2% | ||
| Profit Before Tax (PBT) | -1 | -2 ▼ 96.6% | 1 ▲ 150.8% | |
-1 | 1 ▲ 163.2% | 4 ▲ 486.1% | ||
| Effective Tax %Derived | 141.54% | -45.52% | 525.40% | |
| Total Profit for Period | 0 | -2 ▼ 788.7% | -3 ▼ 48.5% | |
| Net Profit (Owner's PAT)Derived | 0 | -2 ▼ 788.7% | -3 ▼ 48.5% | |
| Net Profit Margin %Derived | 0.18% | -1.65% | -1.38% | |
| PAT Growth YoY %Derived | — | -788.67% | -48.46% | |
| Earnings Per Share (EPS ₹) | 0.06 | -0.41 ▼ 783.3% | -0.60 ▼ 46.3% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% | 5 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 113.7% | 0 ▲ 117.5% | |
| Total Expenses (incl. D&A & Interest) | 193 | 140 ▼ 27.1% | 239 ▲ 70.3% | |
| Material Cost % of RevenueDerived | 93.04% | 84.10% | 80.35% | |
| Employee Cost % of RevenueDerived | 2.37% | 3.29% | 2.95% | |
| Other Cost % of RevenueDerived | 9.83% | 12.80% | 11.33% | |
| Interest Coverage (x)Derived | -133.30x | -38.63x | 0.18x |
VALIANTLAB segment analysis : revenue and profit mix.
Disclosed business segments at VALIANTLAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
VALIANTLAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for VALIANTLAB.
Our AI distills the core fundamental drivers supporting VALIANTLAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
VALIANTLAB's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter confidence remains high with 74.9% consistent shareholding.
Robust quarterly sales growth of 148% to 46.8 Cr.
Impressive 457% quarterly PAT growth signals potential operational turnaround.
Manageable debt-to-equity ratio of 0.52 indicates healthy financial structure.
Specialization in paracetamol, a globally demanded API, ensures market relevance.
Key Risks.
Exceptionally high P/E ratio of 3357.61 suggests significant overvaluation.
Negative ROE (-1.43%) and ROCE (-0.95%) indicate inefficient capital utilization.
Negative operating profit margin (-1.23%) highlights operational efficiency challenges.
Significant decline in FII/DII holdings signals waning institutional investor confidence.
Negative 3-year revenue growth (-13.80%) shows declining top-line trend.
Flip Conditions.
Valuation risk. a P/E above 52 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
VALIANTLAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VALIANTLAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
VALIANTLAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for VALIANTLAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
VALIANTLAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VALIANTLAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VALIANTLAB stood at 49.0% of traded volume, against a 20-day average of 73.9%.
VALIANTLAB announcements: results, concalls, ratings, M&A.
Filings VALIANTLAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VALIANTLAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 80 documents below.
Trading Window
Valiant Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Shareholders meeting
Valiant Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the…
Shareholders meeting
Valiant Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 28, 2026
General Updates
Valiant Laboratories Limited has informed the Exchange about Investment in AMPYR Renewable Energy Resources Twelve A Private Limited
Copy of Newspaper Publication
Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to…
Investor decks & rating reports.
VALIANTLAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VALIANTLAB has declared, sequenced by announce and record date.
VALIANTLAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About VALIANTLAB: business, sector, key facts.
What VALIANTLAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VALIANTLAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: VALIANTLAB, BSE: 543998.
Valiant Laboratories Limited is an active pharmaceutical ingredient (API) and bulk drug manufacturing company with a global reach, headquartered in Mumbai, India. Their primary focus is on the production and distribution of paracetamol, a widely used analgesic and antipyretic drug. They manufacture paracetamol to meet the standards of various pharmacopoeias, including those of India, Britain, Europe, and the United States, ensuring compliance with diverse regulatory requirements across different markets.
The company's paracetamol production caters to a broad range of therapeutic applications. It is used to treat a variety of conditions including headaches, muscle aches, arthritis, backaches, toothaches, cold symptoms, and fever. This broad applicability contributes to a large potential market for their product.
Beyond paracetamol, Valiant Laboratories also offers a portfolio of specialty chemicals, though the specifics of these offerings are not detailed in the provided information. This diversification suggests a commitment to offering a wider range of products and services within the chemical and pharmaceutical industries.
Established in 1980 as Bharat Chemicals, the company rebranded as Valiant Laboratories Limited in August 2021. This rebranding may reflect a strategic shift in focus or an effort to enhance brand image and market positioning. Currently, Valiant Laboratories Limited operates as a subsidiary of Dhanvallabh Ventures LLP, indicating a larger corporate structure and potential access to greater resources and support.
In summary, Valiant Laboratories Limited is a well-established pharmaceutical company specializing in the manufacture and distribution of high-quality paracetamol and other specialty chemicals, supplying to a global market and meeting the stringent standards of multiple international pharmacopoeias. Their long history and recent rebranding demonstrate a commitment to sustained growth and innovation within the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about VALIANTLAB (VALIANTLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of VALIANTLAB (VALIANTLAB)?
The current share price of VALIANTLAB (VALIANTLAB) is ₹104.89. Today, the stock has declined by ₹2.98 (2.76%), trading in a range of ₹103.00 to ₹109.20. The stock opened at ₹107.87 with a trading volume of 3,63,930 shares.
02Is VALIANTLAB stock a good investment for long-term?
VALIANTLAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹635.73 Cr., P/E ratio of 39.68, ROE of 1.74%, and ROCE of 1.84%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of VALIANTLAB stock?
The 52-week high price of VALIANTLAB (VALIANTLAB) is ₹110.70, while the 52-week low is ₹49.51. Currently trading at ₹104.89, the stock is 111.86% above its 52-week low and 5.25% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy VALIANTLAB stock at the current price?
Whether to buy VALIANTLAB stock at ₹104.89 depends on multiple factors. The stock is currently trading with a P/E ratio of 39.68 and P/B ratio of 2.04. Today's performance shows a loss of 2.76%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of VALIANTLAB and when is the next dividend?
VALIANTLAB offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹104.89, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of VALIANTLAB?
VALIANTLAB's key financial metrics include: P/E Ratio: 39.68, P/B Ratio: 2.04, ROE: 1.74%, ROCE: 1.84%, Dividend Yield: 0%, EPS: ₹1.75, Book Value: ₹57.24, and Debt-to-Equity: 0. The company's market cap stands at ₹635.73 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is VALIANTLAB stock performing today in the market?
VALIANTLAB stock opened at ₹107.87 and is currently trading at ₹104.89, showing a decline of ₹2.98 (2.76%). The intraday high is ₹109.20 and low is ₹103.00. The trading volume stands at 3,63,930 shares, indicating moderate market participation today.
08What is the P/E ratio of VALIANTLAB and what does it indicate?
VALIANTLAB has a Price-to-Earnings (P/E) ratio of 39.68, which means investors are willing to pay 39.68 for every ₹1 of earnings. With an EPS of ₹1.75, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about VALIANTLAB (VALIANTLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.